Daniely, David Forouzan, Eli Spektor, Tanya M Cohen, Alexa Bitran, Jacob D Chen, Gigi Moezi, Mehdi M Bessudo, Alberto Hrom, John Eshaghian, Shahrooz
...
Published in
Experimental hematology
Identifying effective combination regimens is a high priority in multiple myeloma (MM), as most patients eventually become refractory to their current treatments. In this study, we investigated whether the proteasome inhibitor (PI) ixazomib could delay disease progression among patients who failed regimens containing another PI, bortezomib or carfi...
Kropp, Erin M Li, Qing
Published in
Experimental hematology
Acute myeloid leukemia (AML) is an aggressive disease of clonal hematopoiesis with a high rate of relapse and refractory disease despite intensive therapy. Traditionally, relapsed or refractory AML has increased therapeutic resistance and poor long-term survival. In recent years, advancements in the mechanistic understanding of leukemogenesis have ...
Kellaway, Sophie G Coleman, Daniel J L Cockerill, Peter N Raghavan, Manoj Bonifer, Constanze
Published in
Experimental hematology
The transcription factor RUNX1 is essential for correct hematopoietic development; in its absence in the germ line, blood stem cells are not formed. RUNX1 orchestrates dramatic changes in the chromatin landscape at the onset of stem cell formation, which set the stage for both stem self-renewal and further differentiation. However, once blood stem ...
Rostami, Tahereh Mousavi, Seyed Ali Kiumarsi, Azadeh Kasaeian, Amir Rad, Soroush Yaghmaie, Marjan Ghavamzadeh, Ardeshir Mousavi, Seied Asadollah
Published in
Experimental hematology
Fanconi anemia (FA) is a rare and complex genetic disorder, clinically characterized by bone marrow failure, congenital defects, and cancer predisposition. Hematopoietic stem cell transplantation (HSCT) represents the only therapeutic option to restore normal hematopoiesis after the occurrence of marrow failure or clonal hematopoietic abnormality. ...
Hidalgo, Isabel Wahlestedt, Martin Yuan, Ouyang Zhang, Qinyu Bryder, David Pronk, Cornelis Jan
Published in
Experimental hematology
The Polycomb complex protein Bmi1 is regarded as a master regulator of hematopoietic stem cells (HSCs). In the blood system, HSCs express Bmi1 most abundantly, and Bmi1 expression wanes as cells differentiate. Furthermore, Bmi1 has been found to be overexpressed in several hematologic cancers. Most studies exploring the normal role of Bmi1 in HSC b...
Can, Ismail Cox, Michelle J Siegler, Elizabeth L Sakemura, Reona Kenderian, Saad S
Published in
Experimental hematology
Development of chimeric antigen receptor T cell (CART) therapy has led to an unprecedented success against B-cell leukemia and lymphoma and resulted in U.S. Food and Drug Administration-approved treatment protocols. Despite the initial clinical response in B cell-related malignancies, high relapse rates suggest that much work is needed to uncover m...
Redondo Monte, Enric Leubolt, Georg Windisch, Roland Kerbs, Paul Dutta, Sayantanee Landspersky, Theresa Istvánffy, Rouzanna Oostendorp, Robert A J Chen-Wichmann, Linping Herold, Tobias
...
Published in
Experimental hematology
GATA2 zinc-finger (ZF) mutations are associated with distinct entities of myeloid malignancies. The specific distribution of these mutations points toward different mechanisms of leukemogenesis depending on the ZF domain affected. In this study, we compared recurring somatic mutations in ZF1 and ZF2. All tested ZF mutants disrupted DNA binding in v...
Zhang, JinFang Liu, XiaoLi Yin, ChangXin Zong, Sa
Published in
Experimental hematology
This study sought to clarify the role of heterogeneous nuclear ribonucleoprotein K (hnRNPK) as a regulator of imatinib resistance in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Expression of hnRNPK was assessed in Ph+ ALL leukemia cells in vitro and in vivo, and imatinib susceptibility was assessed via CCK-8 assay. In c...
Klempnauer, Karl-Heinz
Published in
Experimental hematology
Transcription factor MYB is a key regulator of gene expression in hematopoietic cells and has emerged as a novel drug target for acute myeloid leukemia (AML). Studies aiming to identify potential MYB inhibitors have found that the natural compound helenalin acetate (HA) inhibits viability and induces cell death and differentiation of AML cells by d...
Kapadia, Bandish Shetty, Amol C Bollino, Dominique Bhandary, Binny Lapidus, Rena G Mahmood, Kanwal Mahurkar, Anup Gartenhaus, Ronald B Eckert, Richard L Emadi, Ashkan
...
Published in
Experimental hematology
The clinical outcomes of patients with acute myeloid leukemia (AML) treated with available therapy remain unsatisfactory. We recently reported that the BCL-2 inhibitor venetoclax synergizes with pegcrisantaspase (Ven-PegC) and exhibits remarkable in vivo efficacy in a preclinical model of AML with complex karyotype. The Ven-PegC combination blocks ...
